203 related articles for article (PubMed ID: 18347181)
1. Irinotecan pharmacogenetics: influence of pharmacodynamic genes.
Hoskins JM; Marcuello E; Altes A; Marsh S; Maxwell T; Van Booven DJ; Paré L; Culverhouse R; McLeod HL; Baiget M
Clin Cancer Res; 2008 Mar; 14(6):1788-96. PubMed ID: 18347181
[TBL] [Abstract][Full Text] [Related]
2. Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
Lévesque E; Bélanger AS; Harvey M; Couture F; Jonker D; Innocenti F; Cecchin E; Toffoli G; Guillemette C
J Pharmacol Exp Ther; 2013 Apr; 345(1):95-101. PubMed ID: 23386248
[TBL] [Abstract][Full Text] [Related]
3. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
Chen S; Villeneuve L; Jonker D; Couture F; Laverdière I; Cecchin E; Innocenti F; Toffoli G; Lévesque E; Guillemette C
Pharmacogenet Genomics; 2015 Dec; 25(12):573-83. PubMed ID: 26352872
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of irinotecan disposition and toxicity: a review.
Fujita K; Sparreboom A
Curr Clin Pharmacol; 2010 Aug; 5(3):209-17. PubMed ID: 20406168
[TBL] [Abstract][Full Text] [Related]
5. [Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer].
Teruya T; Nakachi A; Shimabukuro N; Toritsuka D; Azuma Y; Hanashiro K; Nishiki T; Ota M; Shimabuku M; Shiroma H
Gan To Kagaku Ryoho; 2015 May; 42(5):585-9. PubMed ID: 25981652
[TBL] [Abstract][Full Text] [Related]
6. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.
Lamas MJ; Duran G; Balboa E; Bernardez B; Candamio S; Vidal Y; Mosquera A; Giraldez JM; Lopez R; Carracedo A; Barros F
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1591-9. PubMed ID: 22535333
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.
Hoskins JM; Rosner GL; Ratain MJ; McLeod HL; Innocenti F
Pharmacogenomics; 2009 Jul; 10(7):1139-46. PubMed ID: 19604089
[TBL] [Abstract][Full Text] [Related]
8. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
de Jong FA; Scott-Horton TJ; Kroetz DL; McLeod HL; Friberg LE; Mathijssen RH; Verweij J; Marsh S; Sparreboom A
Clin Pharmacol Ther; 2007 Jan; 81(1):42-9. PubMed ID: 17185998
[TBL] [Abstract][Full Text] [Related]
10. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.
Teft WA; Welch S; Lenehan J; Parfitt J; Choi YH; Winquist E; Kim RB
Br J Cancer; 2015 Mar; 112(5):857-65. PubMed ID: 25611302
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Innocenti F; Ratain MJ
Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
Minami H; Sai K; Saeki M; Saito Y; Ozawa S; Suzuki K; Kaniwa N; Sawada J; Hamaguchi T; Yamamoto N; Shirao K; Yamada Y; Ohmatsu H; Kubota K; Yoshida T; Ohtsu A; Saijo N
Pharmacogenet Genomics; 2007 Jul; 17(7):497-504. PubMed ID: 17558305
[TBL] [Abstract][Full Text] [Related]
13. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between UGT1A and irinotecan-related toxicity].
Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):241-3. PubMed ID: 23985249
[No Abstract] [Full Text] [Related]
15. A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients.
Chen S; Laverdiere I; Tourancheau A; Jonker D; Couture F; Cecchin E; Villeneuve L; Harvey M; Court MH; Innocenti F; Toffoli G; Lévesque E; Guillemette C
Pharmacogenomics J; 2015 Dec; 15(6):513-20. PubMed ID: 25778466
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
17. Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients.
Mbatchi LC; Robert J; Ychou M; Boyer JC; Del Rio M; Gassiot M; Thomas F; Tubiana N; Evrard A
Clin Pharmacokinet; 2016 Sep; 55(9):1145-57. PubMed ID: 27116457
[TBL] [Abstract][Full Text] [Related]
18. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
Cecchin E; Innocenti F; D'Andrea M; Corona G; De Mattia E; Biason P; Buonadonna A; Toffoli G
J Clin Oncol; 2009 May; 27(15):2457-65. PubMed ID: 19364970
[TBL] [Abstract][Full Text] [Related]
19. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
Mehra R; Murren J; Chung G; Smith B; Psyrri A
Clin Colorectal Cancer; 2005 May; 5(1):61-4. PubMed ID: 15929808
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K
Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
